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Human carcinogen 1,3-butadiene (BD) undergoes metabolic acti-
vation to 3,4-epoxy-1-butene (EB), hydroxymethylvinyl ketone 
(HMVK), 3,4-epoxy-1,2-butanediol (EBD) and 1,2,3,4-diepoxyb-
utane (DEB). Among these, DEB is by far the most genotoxic 
metabolite and is considered the ultimate carcinogenic spe-
cies of BD. We have shown previously that BD-exposed labora-
tory mice form 8- to 10-fold more DEB–DNA adducts than rats 
exposed at the same conditions, which may be responsible for 
the enhanced sensitivity of mice to BD-mediated cancer. In the 
present study, we have identified 1,4-bis-(N-acetyl-l-cystein-S-yl)
butane-2,3-diol (bis-BDMA) as a novel DEB-specific urinary bio-
marker. Isotope dilution high-performance liquid chromatog-
raphy-electrospray ionization-tandem mass spectrometry was 
employed to quantify bis-BDMA and three other BD-mercapturic 
acids, 2-(N-acetyl-l-cystein-S-yl)-1-hydroxybut-3-ene/1-(N-
acetyl-l-cystein-S-yl)-2-hydroxy-but-3-ene (MHBMA, from EB), 
4-(N-acetyl-l-cystein-S-yl)-1,2-dihydroxybutane (DHBMA, from 
HMVK) and 4-(N-acetyl-l-cystein-S-yl)-1,2,3-trihydroxybutane 
(THBMA, from EBD), in urine of confirmed smokers, occupa-
tionally exposed workers and BD-exposed laboratory rats. Bis-
BDMA was formed in a dose-dependent manner in urine of 
rats exposed to 0–200 p.p.m. BD by inhalation, although it was 
a minor metabolite (1%) as compared with DHBMA (47%) and 
THBMA (37%). In humans, DHBMA was the most abundant 
BD-mercapturic acid excreted (93%), followed by THBMA (5%) 
and MHBMA (2%), whereas no bis-BDMA was detected. These 
results reveal significant differences in metabolism of BD between 
rats and humans.
Introduction
1,3-Butadiene (BD) is a high volume industrial chemical extensively used 
in the production of synthetic rubber, resins and polymers (1,2). BD is 
also an environmental chemical present in automobile exhaust, automo-
tive fuel, forest fires and cigarette smoke (1,2). C57BL/6 × C3H F1 mice 
exposed to 6.25–200 p.p.m. of BD by inhalation developed lymphocytic 
lymphoma and tumors of the heart, lung, forestomach, Harderian gland, 
preputial gland, liver, mammary gland and the ovary (3). Sprague-
Dawley rats exposed to 1000–8000 p.p.m. BD exhibited neoplasms in the 
mammary gland, brain, Zymbal gland, uterus, pancreas, testis and thyroid 
gland (4). Occupational exposure of humans to BD is associated with 
an increased risk of leukemia, lymphatic and hematopoietic cancer (5,6). 
Based on the above evidence, BD has been classified as a known human 
carcinogen in the Twelfth Annual Report on Carcinogens published by 
the National Toxicology Program (2011) (1).
Although the exact mechanisms of BD-mediated cancer are 
unknown, metabolic activation of BD to DNA-reactive intermediates 
is required for its genotoxic and carcinogenic activity (7). BD is ini-
tially metabolized to (R,S)-3,4-epoxy-1-butene (EB), which can be 
further oxidized to form 1,2,3,4-diepoxybutane (DEB) or hydrolyzed 
to 1-butene-3,4-diol (EB-diol) (Scheme 1)  (2). EB-diol can in turn 
undergo CYP450 2E1-mediated oxidation to 3,4-epoxy-1,2-butan-
ediol (EBD) (2) or alcohol dehydrogenase-mediated conversion to 
hydroxymethylvinyl ketone (HMVK) (8) (Scheme 1). Although all 
BD-derived epoxides are direct mutagens (2), DEB is 30-fold more 
genotoxic than EB and 100-fold more mutagenic than EB-diol (9), 
probably due to its bifunctional nature that enables DEB to cross-
link cellular biomolecules. Epoxide hydrolase-mediated hydrolysis 
appears to be the predominant pathway of metabolic deactivation of 
EB, DEB and EBD in rats and humans (2,10).
If not inactivated, BD-derived electrophilic metabolites can mod-
ify DNA nucleobases to give a wide range of adducts. EB-mediated 
alkylation generates N7-(2-hydroxy-3-buten-1-yl)guanine (EB-Gua 
I), N7-(1-hydroxy-3-buten-2-yl)guanine (EB-Gua II), N3-(2-hydroxy-
3-buten-1-yl)adenine (EB-Ade I) and N3-(1-hydroxy-3-buten-2-yl) 
(EB-Ade II) (7). DNA alkylation by DEB initially produces 2-hydroxy-
3,4-epoxybut-1-yl monoadducts (11,12), which can be hydrolyzed 
to the corresponding N7-(2,3,4-trihydroxy-3-buten-2-yl) lesions 
or can further react with another nucleophilic site of DNA to form 
exocyclic deoxyadenosine lesions such as 1,N6-(1-hydroxymethyl-
2-hydroxypropan-1,3-diyl)-2′-deoxyadenosine (13,14), DNA–DNA 
cross-links (15–18) and DNA–protein cross-links (19,20).
Previous studies in laboratory animals have revealed significant 
species and gender differences in susceptibility to BD, which have 
been attributed to differences in metabolism. Specifically, laboratory 
mice developed tumors at ~200-fold lower BD concentrations than 
rats (3,4), supposedly a result of higher BD bioactivation/detoxifica-
tion ratio in the mouse (21,22). Epoxide hydrolase-mediated hydroly-
sis of DEB was more efficient in human liver microsomes than in rat 
microsomes, and negligible in mouse microsomes (22). Female mice 
were more susceptible to BD-mediated cancer than males exposed at 
the same conditions (3) and exhibited greater numbers of DNA–DNA 
cross-links than males (23). In contrast, hemoglobin adduct measure-
ments in BD-exposed Czech workers suggested that females absorbed 
or metabolized BD to a lesser extent than males (24). If present, any 
interspecies and gender differences in metabolism of BD are critically 
important for human cancer risk assessment.
Urinary metabolites can provide a sensitive, non-invasive meas-
ure of carcinogen metabolism to the ultimate tumorigenic spe-
cies. As shown in Scheme 1, EB, HMVK and EBD are excreted 
in urine as 2-(N-acetyl-L-cystein-S-yl)-1-hydroxybut-3-ene/1-
(N-acetyl-L-cystein-S-yl)-2-hydroxy-but-3-ene (MHBMA), 
4-(N-acetyl-L-cystein-S-yl)-1,2-dihydroxybutane (DHBMA) and 4-(N-
acetyl-L-cystein-S-yl)-1,2,3-trihydroxybutane (THBMA), respectively 
(25–31). By analogy, DEB is expected to be conjugated with two mol-
ecules of glutathione and be excreted in urine as the corresponding 
bis-mercapturic acid, 1,4-bis-(N-acetyl-l-cystein-S-yl)butane-2,3-diol 
(bis-BDMA, Scheme 1). However, to our knowledge, such bis-conjugates 
had not been previously reported. We hypothesized that bis-BDMA, if 
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formed in vivo, can serve as a non-invasive biomarker of BD metabolism 
to its ultimate carcinogenic species, DEB. To test this hypothesis, we pre-
pared synthetic bis-BDMA and developed a sensitive isotope dilution 
high-performance liquid chromatography (HPLC)-ESI−-MS/MS method 
for its analysis following in vivo formation. The new methodology was 
used to quantify bis-BDMA in urine of F344 rats exposed to 0–200 p.p.m. 
BD, workers occupationally exposed to BD, and confirmed smokers. 
Other BD-mercapturic acids (MHBMA, DHBMA and THBMA) were 
also measured to obtain a complete picture of BD metabolism. Finally, 
we have employed nanoHPLC-NSI+-MS/MS to detect DEB-induced 
DNA–DNA cross-links in liver tissues of BD-treated rats. Our results 
reveal important interspecies differences in the metabolic pathways of BD.
Materials and methods
Materials
N-acetyl-l-cysteine and HPLC-mass spectrometry (MS) grade formic acid 
were purchased from Sigma–Aldrich (St Louis, MO). HPLC-MS grade meth-
anol and acetonitrile were obtained from Fisher Scientific (Pittsburgh, PA). 
All other chemicals and reagents were from Sigma–Aldrich. Isolute ENV+ 
50 mg/1 ml solid phase extraction (SPE) cartridges were purchased from 
Biotage (Charlotte, NC). R, R-Diepoxybutane was synthesized as reported 
previously (17). MHBMA, DHBMA, 2H6-MHBMA, 
2H7-DHBMA and
 2H3-N-
acetyl-l-cysteine were obtained from Toronto Research Chemicals (Toronto, 
Ontario, Canada). THBMA and 2H3-THBMA standards were available from a 
previous study (31). Bis-BDMA and 2H6-bis-BDMA were synthesized in our 
laboratory as described below.
Synthesis of bis-BDMA and its deuterated analog (2H6-bis-BDMA)
N-acetyl-l-cysteine (280 mg, 1.70 mmol) was dissolved in 8 ml of water, and 
the pH of the solution was adjusted to 10 with 1N NaOH. R, R-Diepoxybutane 
(17) (75 mg, 0.85 mmol) was added, and the reaction mixture was stirred at room 
temperature for 4 h. At the end of the reaction, sodium ions were removed by 
the addition of Bio-Rad AG 50W-X8 cation exchange resin, followed by filtra-
tion. Bis-BDMA was isolated by semi-preparative HPLC using an Agilent 1100 
HPLC system interfaced to a DAD UV detector (Agilent Technologies, Santa 
Clara, CA). HPLC separation was achieved with a Synergi Hydro RP column (250 
× 10.00 mm; 4 μ) (Phenomenex, Torrance, CA) using isocratic elution with 6% 
acetonitrile in 0.1% trifluoroacetic acid/water. Under these conditions, bis-BDMA 
eluted as sharp peak at 19.6 min. HPLC fractions containing bis-BDMA (19.0–
20.2 min) were manually collected and concentrated under vacuum to yield a white 
powder. 2H6-bis-BDMA was similarly synthesized starting with 
2H3-N-acetyl-l-
cysteine (Supplementary Scheme S1, available at Carcinogenesis Online).
Bis-BDMA and 2H6-bis-BDMA were structurally characterized by nuclear 
magnetic resonance (NMR) and high resolution mass spectrometry. 1H NMR 
of bis-BDMA (Supplementary Figure S1, available at Carcinogenesis Online): 
δ 8.3 (2H, s, cys-NH), 4.4 (2H, m, αC-cys), 3.7 (2H, s, internal OH), 3.6 
(2H, m, CHOH), 3.0-2.8 (4H, m, βC-cys), 2.7-2.5 (4H, m, SCH2), 1.9 (6H, 
s, COCH3) (Supplementary Figure S1, available at Carcinogenesis Online). 
High resolution mass spectrometry results (Figure 1A): bis-BDMA (ESI−-MS: 
411.0905 [M-H]−, MS/MS: 282.0468, 153.0042 and 128.0348); 2H6-bis-
BDMA (ESI−-MS: 417.1275 [M-H]−, MS/MS: 285.0668, 153.0045 and 
131.0544). Stock solutions of bis-BDMA and 2H6-bis-BDMA were prepared 
in water and stored at −20°C.
Animals and treatment
All procedures involving the use of animals were approved by the Institutional 
Animal Care and Use Committee. Male and female F344 rats (aged 27–29 days) 
were purchased from Charles River Breeding Laboratories (Raleigh, NC) and 
housed in cages with animal chow and water in temperature- and humidity-
controlled rooms with a 12 h light/dark cycle (NIH Publication 86-23, 1985) at 
the Environmental Exposure and Inhalation Health Facility (at the University 
of Texas Medical Branch at Galveston). Following a 7 day acclimation period, 
the animals were randomly separated into air control and exposure groups. Rats 
were exposed whole body to nominal 62.5 or 200 p.p.m. BD in air for 2 weeks 
(6 h/day, 5 days/week) in Hinnar exposure chambers. Rats in the third chamber 
received filtered air only as a control group. Stock BD (99+ %; from Air Gas 
Southwest, Texas City, TX) was metered using mass flow valve, diluted with 
filtered room air and pumped into the exposure chambers. BD concentrations in 
exposure chambers were determined by gas chromatography using a Shimadzu 
GC-17A gas chromatograph equipped with a DB-1 GC column and an FID 
detector. Fresh animal chow and water were provided during the exposure 
period. Following exposures, the leftover food and water were discarded, and the 
animals were returned to their appropriate housing box until the next exposure.
To enable urine collection from BD-exposed animals, groups of female 
and male rats (n = 4 per exposure level and sex) were randomly selected and 
Scheme 1. Metabolic pathways of 1,3-butadiene and the formation of urinary mercapturic acids, MHBMA, DHBMA, THBMA and bis-BDMA.
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transferred from exposure chambers into metabolic cages at the end of the 7th 
or the 8th day of BD exposure. Rats were held in metabolic cages, with access 
to food and water, until the next exposure period, when they were returned to 
Hinnar exposure chambers. Urine excreted by individual rats during overnight 
housing in metabolic cages was placed in Eppendorf tubes, snap frozen, and 
stored at −80°C. Water and food were provided in a separate area to prevent the 
introduction of drinking water into urine collection tubes.
At the end of the final exposure period, animals were euthanized via cardiac 
puncture. Liver and lung tissues were collected, flash frozen in liquid nitrogen, 
and stored at −80°C. Frozen urine and liver tissue samples were shipped on 
dry ice to the University of Minnesota, where they were stored at −80°C until 
analysis.
Human subjects
For the occupational exposure study, 72 subjects working in a BD production 
facility were included (Supplementary Table S1, available at Carcinogenesis 
Online). Of these, 40 were controls (administrative workers) and 32 were BD 
production workers. BD exposures were determined by personal monitoring 
tubes for 8 h work shifts on 10 separate occasions over a 4 month interval 
for each study subject. The details of the occupational exposure study have 
been reported previously (32). The experimental protocol was approved by 
the Institutional Review Boards at Regional Institute of Hygiene of Central 
Bohemia and the University of Vermont. Archived urine samples were shipped 
to the University of Minnesota on dry ice and stored at −80°C.
Smoker urine samples (n  =  36, overnight or 24 h urine collection, 
Supplementary Table S1, available at Carcinogenesis Online) were obtained 
from the University of Minnesota Tobacco Research Programs and the 
University of Hawaii Cancer Center. Smoking status was confirmed by coti-
nine analysis.
Quantitation of bis-BDMA
Rat or human urine samples (100 μl) were vortexed and mixed with 100 μl 
of 50 mM ammonium formate buffer (pH 2.5) and 10 μl of formic acid. 2H6-
bis-BDMA internal standard (60 ng) was added, and the samples were mixed 
and centrifuged at 13 000 r.p.m. for 15 min. The supernatant was loaded onto 
Isolute ENV+ cartridges (1 ml/50 mg) preconditioned with methanol (3 ml) and 
0.3% formic acid (3 ml). The cartridges were washed with 1.5 ml of 0.3% for-
mic acid, followed by 0.75 ml of 5% methanol in 0.3% formic acid and dried 
under vacuum for 20 min. Bis-BDMA and its internal standard were eluted 
with 1.2 ml of 2% formic acid in methanol. SPE eluates were concentrated 
under vacuum and reconstituted in 30 μl of water. Typically, 3 μl of this solu-
tion was injected onto the HPLC column for HPLC-ESI−-MS/MS analysis.
HPLC-ESI−-MS/MS analysis of bis-BDMA was conducted with an Agilent 
1100 HPLC system (Agilent Technologies) coupled with a Thermo-Finnigan 
TSQ Quantum Discovery mass spectrometer (Thermo Scientific Corp., 
Waltham, MA). HPLC separations were carried out on a SIELC Primesep D 
column (2.1 × 100 mm, 5  μm particle size) equipped with a guard column 
(Primesep D; 2.1 × 10 mm). The column was maintained at 50°C and eluted 
with a gradient of water (solvent A) and 1% formic acid in 50% acetoni-
trile (solvent B), at a flow rate of 200 μl/min. Gradient program was as fol-
lows (time, % of solvent B): 0–8 min, 40 to 48% B; 8–10 min, 48 to 75% 
B; 10–13 min, isocratic at 75% B; 13–15 min, 75 to 40% B; 15–25 min, final 
equilibration at 40% B. The HPLC eluent was directed into the MS detector 
during 4.5–10 min of the chromatographic run.
The TSQ Vantage triple quadrupole instrument (Thermo Scientific), was 
operated in the negative electrospray ionization (ESI−) mode. Typical MS 
parameters were as follows: spray voltage, −3500 V; sheath gas pressure, 50 
psi; capillary temperature, 250°C; collision energy, 16; source CID, −9 V; col-
lision gas pressure, 1.0 mTorr; Q1 (full width at half maximum), 0.4; Q3 (full 
width at half maximum), 0.7; scan width, 0.4 m/z and scan time, 0.4 s. The 
MS parameters were optimized by direct infusion of authentic standards and 
may differ between runs. The mass spectrometer was operated in the selected 
reaction monitoring (SRM) mode. The SRM transitions used for quantification 
of bis-BDMA were: m/z 411.1 → 282.1 (bis-BDMA) and m/z 417.1 → 285.1 
(2H6-bis-BDMA internal standard). For confirmation purposes, additional 
SRM transitions were also monitored (m/z 411.1 → 153.1, 411.1 → 128.1 
for bis-BDMA and m/z 417.1 → 153.1, 417.1 → 131.1 for 2H6-bis-BDMA). 
HPLC-ESI−-MS/MS methodology was fully validated by analyzing control 
rat urine spiked with known amounts of bis-BDMA and 2H6-bis-BDMA. 
Method limit of detection (LOD), limit of quantification, precision, accu-
racy, SPE recovery, and matrix effects were determined as described in the 
Supplementary Materials and methods, available at Carcinogenesis Online.
Quantitative analysis of MHBMA, DHBMA and THBMA
Rat or human urine samples (200  μl) were spiked with 60 ng each of 2H6-
MHBMA and 2H7-DHBMA and processed by SPE on Waters Oasis HLB 
cartridges. The SPE eluates were dried, reconstituted in 30 μl of 0.1% formic 
acid and analyzed by HPLC-ESI−-MS/MS using a Pursuit 3 Diphenyl column 
(2.1 × 150 mm, 3 µm) eluted with a gradient of 0.1% formic acid and acetoni-
trile. For quantitative analysis of THBMA, urine aliquots (100 μl) were spiked 
with 2H3-THBMA internal standard, and, processed by Isolute ENV+ SPE as 
described previously (31). The HPLC-ESI−-MS/MS conditions for analysis of 
THBMA were same as described above for bis-BDMA, except that the gradi-
ent program was modified as follows (time, % of solvent B): 0–6 min, 15 to 
21% B; 6–9 min, 21 to 75% B; 9–12 min, isocratic at 75% B; 12–15 min, 75 to 
15% B; 13–25 min, finally maintained at 15% B.
Determination of bis-N7G-BD adducts in rat liver DNA
NanoHPLC-NSI+-MS/MS methodology developed in our laboratory (18) 
was used to quantify DEB-induced bis-N7G-BD cross-links in liver DNA 
of rats exposed to 0, 62.5 or 200 p.p.m. BD by inhalation. In brief, DNA 
was extracted using NucleoBond AXG500 anion exchange cartridges 
(Machery-Nagel, Düren, Germany). DNA concentrations were determined 
by HPLC-UV analysis of dG in enzymatic digests (18). DNA (100 μg) was 
spiked with 50 fmol of 15N10-bis-N7G-BD (internal standard for quantita-
tion) and subjected to neutral thermal hydrolysis at 70°C for 1 h to release 
N7-guanine adducts as free bases. Partially depurinated DNA was removed 
by ultrafiltration. Bis-N7G-BD and its internal standard were enriched by 
offline HPLC and reconstituted in 0.01% aqueous acetic acid. Samples (8 
μl) were injected onto a trap column connected to a manually packed Zorbax 
SB-C18 nano HPLC column (75 μm × 200 mm, 5 μ), which was eluted with 
0.01% acetic acid in 1:1 methanol:acetonitrile. Bis-N7G-BD cross-links were 
quantified by isotope dilution nanoHPLC-NSI+-MS/MS. The SRM transi-
tions for bis-N7G-BD and 15N10-bis-N7G-BD internal standard were m/z 
389.1 [M + H]+ → m/z 238.1 [M + H – Gua]+ and m/z 399.1 [15N10-M+H]
+ 
→ m/z 243.1 [M + H − [15N5]Gua]
+, respectively. Accurate quantification 
of bis-N7G-BD was achieved by comparing the areas of nanoHPLC-NSI+-
MS/MS peaks corresponding to the analyte and its internal standard using 
standard curves (18).
Results
Development of HPLC-MS/MS methodology for bis-BDMA
It has been proposed that the susceptibility of a given organism toward 
BD-induced cancer is determined by the extent of metabolic activation 
of BD to its ultimate carcinogenic metabolite, DEB (21). In support 
of this notion, we have previously reported that DNA of laboratory 
mice (more sensitive species) contained 5- to 10-fold greater numbers 
of DEB-specific bis-N7G-BD adducts than rats (less sensitive spe-
cies) exposed at the same conditions (23). However, human tissue and 
blood samples are not readily available for biomarker analysis. We 
therefore examined the feasibility of using urinary bis-BDMA as a 
novel, non-invasive biomarker of BD bioactivation to DEB.
Authentic standards of bis-BDMA and its deuterated analog were 
prepared by reacting DEB with N-acetyl-l-cysteine and 2H3-N-acetyl-
l-cysteine, respectively (Supplementary Scheme S1, available at 
Carcinogenesis Online). Both standards were characterized by proton 
NMR (Supplementary Figure S1, available at Carcinogenesis Online) 
and high resolution mass spectrometry (Figure 1A) and were used for 
the development of an isotope dilution HPLC-ESI-MS/MS method 
for bis-BDMA in urine. In our approach, bis-BDMA is isolated by 
SPE and quantified by HPLC-ESI−-MS/MS using isotope dilution 
with the corresponding deuterated internal standard (2H6-bis-BDMA).
Our HPLC-ESI−-MS/MS method for bis-BDMA is based on 
selected reaction monitoring of MS/MS transitions corresponding to 
the C-S bond cleavage (m/z 411.1 → 282.1 for the analyte and m/z 
417.1  → 285.1 for the deuterated internal standard, respectively, 
Figure 1B). Analysis of standard solutions containing fixed amounts 
of 2H6-bis-BDMA internal standard and increasing amounts of bis-
BDMA confirmed that HPLC-ESI−-MS/MS responses were linear 
between 0.05–160 ng of bis-BDMA (on column) (Supplementary 
Figure S2A, available at Carcinogenesis Online). Further method 
validation was conducted by spiking control rat urine (100 μl) with 
2H6-bis-BDMA (60 ng) and bis-BDMA (0.5–1600 ng), followed by 
SPE and HPLC-ESI−-MS/MS analysis. An excellent correlation was 
observed between the measured and the expected concentrations of 
bis-BDMA (Supplementary Figure S2B, available at Carcinogenesis 
Online) (R2  =  0.9999). HPLC-ESI−-MS/MS LOD and limit of 
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quantification for bis-BDMA in human urine were determined to be 
1 and 5 ng/ml, respectively (Supplementary Table S2, available at 
Carcinogenesis Online). The intraday and interday precision (% rel-
ative standard deviation) of our analytical method determined by 
repeated analysis of bis-BDMA (100 ng) spiked into control rat urine 
sample (100  µl) were 0.88 and 1.17%, respectively. Comparison of 
HPLC-ESI−-MS/MS peak areas in the presence and in the absence of 
rat urine matrix (post-SPE) revealed a minimal signal suppression of 
the analyte by the sample matrix (<2%). Method accuracy was deter-
mined to be 96.2–100.5%. Freeze-thaw stability studies of bis-BDMA 
in a non-smoker urine have revealed minimal analyte losses over time. 
Complete HPLC-ESI−-MS/MS method validation parameters are com-
piled in Supplementary Table S2, available at Carcinogenesis Online.
Quantification of BD-mercapturic acids in urine of F344 rats 
exposed to BD by inhalation
The validated HPLC-ESI−-MS/MS method was used to quantify 
bis-BDMA in urine of F344 rats (n = 4 per exposure level and sex) 
treated with 0, 62.5 or 200 p.p.m. BD by inhalation for 2 weeks (6 h/
day, 5 days/week). The concentrations of other BD-mercapturic acids 
(MHBMA, DHBMA and THBMA, Scheme 1) were also determined in 
order to obtain a complete picture of BD metabolism in the rat. A con-
centration-dependent increase in bis-BDMA amounts was observed in 
groups exposed to 62.5 and 200 p.p.m. BD (right panel in Figure 1B, 
Figure 2A), whereas no bis-BDMA was detected in urine of control 
rats exposed to filtered air (left panel in Figure 1B, Figure 2A). The 
identity of bis-BDMA peak observed for exposed rat urine samples 
was further confirmed by examining two additional MS/MS transi-
tions (Supplementary Figure S3, available at Carcinogenesis Online) 
and by reanalyzing the same samples on a different HPLC column 
(Synergi Hydro-RP, data not shown). Authentic bis-BDMA standard 
and the analyte detected in rat urine exhibited identical MS/MS spec-
tra and HPLC retention times (Supplementary Figure S3, available at 
Carcinogenesis Online).
Mean concentrations of bis-BDMA in rat urine following exposure 
to 200 p.p.m. BD were 4.8 ± 2.9 μg/ml, whereas the corresponding 
amounts of MHBMA, DHBMA and THBMA in the same samples 
were 77.9 ± 37.8, 209.5 ± 85.1 and 150.3 ± 59.9 μg/ml, respectively 
(Figure  2). Urinary concentrations of BD-mercapturic acid corre-
lated with BD exposure, with 2- to 3-fold higher amounts observed 
in 200 p.p.m. BD exposure group as compared with 62.5 p.p.m. 
exposure group (Figure 2). Urine samples from unexposed rats con-
tained background levels of MHBMA (68.5 ± 17.1 ng/ml), DHBMA 
(3192.7 ± 533.2 ng/ml) and THBMA (561.7 ± 81.7 ng/ml), consistent 
with previous studies that have observed these metabolites in unex-
posed animals and human subjects due to an unidentified endogenous 
source (25,27,31). In contrast, no bis-BDMA was detected in unex-
posed animals (Figure 1B, left panel and Figure 2A).
Urinary concentrations of bis-BDMA were 2- to 3-fold higher in 
female rats as compared with the male animals exposed under the 
Fig. 1. Full scan accurate mass ESI−-QTOF spectrum of bis-BDMA and 2H6-bis-BDMA obtained on a Waters Acquity UPLC/Synapt G2 QTOF mass 
spectrometer (A) and HPLC-ESI−-MS/MS detection of bis-BDMA in urine of F344 rats exposed to 0 p.p.m. of BD and 62.5 p.p.m. of BD (B).
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same conditions, although the difference was not statistically signifi-
cant (Figure 2A, P = 0.06). In contrast, female rats excreted slightly 
lower levels of MHBMA, DHBMA and THBMA as compared with 
males (P > 0.3, Figure 2C and D). Although these results are sug-
gestive of gender differences in BD metabolism, further studies with 
greater numbers of animals are needed to confirm these initial obser-
vations. The relative molar concentrations of BD-mercapturic acids 
in urine of BD-exposed rats were in the order: DHBMA (47%) > 
THBMA (37%) > MHBMA (15%) > bis-BDMA (1%) (Figure 3A). 
These results are consistent with previous studies that examined 
BD-induced hemoglobin adducts in blood of rats exposed by inhala-
tion (33). Additionally, the relative contribution of bis-BDMA was 
higher in females (1.6–2%) as compared with males (0.6–0.7%) 
(Supplementary Table S3, available at Carcinogenesis Online).
Quantification of BD-mercapturic acids in urine of smokers and 
occupationally exposed workers
To examine the possibility of bis-BDMA formation in humans, two 
populations chronically exposed to BD were examined: smokers and 
occupationally exposed individuals (Supplementary Table S1, avail-
able at Carcinogenesis Online). Workers at a BD polymer production 
plant (n = 32) were exposed to 0.1–2 p.p.m. BD, whereas the cor-
responding controls (office workers, n = 40) were exposed to <0.02 
p.p.m. BD (Supplementary Table S1, available at Carcinogenesis 
Online). Current smokers (n  =  36, 20 ± 7 cigarettes per day) were 
exposed to BD due to its presence in cigarette smoke (~46 μg/cigarette 
in mainstream smoke) (34). For comparison, the other three urinary 
BD-mercapturic acids (MHBMA, DHBMA, THBMA) were also 
analyzed.
Mean urinary concentrations of MHBMA, DHBMA and THBMA 
in exposed workers were 82 ± 138, 3094 ± 4162 and 157 ± 158 ng/mg 
creatinine, respectively. In smokers, the corresponding concentrations 
were 11 ± 12, 631 ± 452 and 31 ± 20 ng/mg creatinine, respectively. 
DHBMA was the major BD metabolite excreted in human urine 
(93%), followed by THBMA (5%) and MHBMA (2%) (Figure 3B). 
In contrast, the concentrations of bis-BDMA in both groups were 
below the LOD of our method (1 ng/ml) (Supplementary Figure S4A, 
available at Carcinogenesis Online). Bis-BDMA was not detectable 
even when a more sensitive capillary HPLC-ESI-MS/MS method 
was employed (LOD, 0.1 ng/ml), (Supplementary Figure S4B, avail-
able at Carcinogenesis Online) or when larger urine volumes were 
analyzed (up to 1 ml, results not shown). These results are consistent 
Fig. 3. Relative contributions of individual mercapturic acids to total 
amounts of BD-mercapturic acids in urine of F344 rats (n = 16) exposed to 
62.5 or 200 p.p.m. BD (A) and smokers (n = 36) (B).
Fig. 2. Concentrations of bis-BDMA (A), MHBMA (B), DHBMA (C) and THBMA (D) in urine of F344 rats exposed to 0, 62.5 or 200 p.p.m. BD by inhalation 
for 2 weeks (6 h/day, 5 days/week). Error bars represent standard deviation values obtained upon analysis of quadruplicates. Statistical significance is represented 
for comparisons between exposed and control samples (P < 0.05). The differences between urinary BD-mercapturic acid concentrations in male and female rats 
were not statistically significant.
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with previous studies of BD metabolism in liver microsomes and 
BD–hemoglobin adduct measurements, which suggested that BD to 
DEB conversion is less efficient in humans than in laboratory rats and 
mice (7,22,35).
Dose–response studies of DEB-derived bis-N7G-BD adducts in rat 
liver DNA
In order to examine the correlation between urinary BD-mercapturic 
acids and BD–DNA adduct concentrations in tissues, DEB-specific 
bis-N7G-BD adducts were quantified in liver DNA of laboratory 
rats exposed to BD by inhalation. NanoHPLC-nanoNSI+-MS/MS 
methodology recently reported by our group (18) was employed in 
these studies. As expected, no bis-N7G-BD was detected in control 
animals (Figure 4A), whereas BD-exposed animals contained signifi-
cant amounts of DEB-induced bis-N7G-BD cross-links (Figure 4B). 
Interestingly, dose–response relationships for bis-N7G-BD adducts in 
rat liver were not linear, with higher adduct numbers observed fol-
lowing exposure to 62.5 p.p.m. BD as compared with 200 p.p.m. BD 
treatment (Figure 4C). As was the case with bis-BDMA, female rats 
produced higher numbers of bis-N7G-BD adducts (1.6 adducts/108 
nucleotides) as compared with males (1.2 adducts/108 nucleotides), 
although this difference was not statistically significant due to the 
small group size (Figure 4).
Discussion
A potent human and animal carcinogen, BD is metabolically activated 
to four electrophilic species: EB, HMVK, EBD and DEB (Scheme 
1)  (2,8). Among these, DEB displays the greatest genotoxicity and 
is considered the ultimate carcinogenic metabolite of BD (2). DEB 
is 50-fold more effective at inducing sister chromatid exchanges and 
chromosomal aberrations in human lymphocytes than EB (36,37) and 
is two orders of magnitude more mutagenic than EB and EBD in TK6 
lymphoblasts (9). More efficient DEB formation from BD in labora-
tory mice is thought to be responsible for their increased sensitiv-
ity to BD-induced cancer as compared with laboratory rats (23,38). 
Previous studies of DEB formation in humans are limited, although 
experiments with human liver microsomes suggest that any DEB 
produced in humans is rapidly detoxified via epoxide hydrolase-cata-
lyzed hydrolysis (22).
Urinary mercapturic acids are commonly used as biomarkers of 
exposure to carcinogens and as a measure of their metabolic activation 
to DNA-reactive intermediates (39). In the present work, bis-BDMA 
was employed as a novel urinary biomarker for DEB formation from 
BD. To our knowledge, bis-BDMA has not been previously reported 
in vivo, although Boogaard et al. (40) detected the formation of a 
conjugation product of DEB with two molecules of glutathione fol-
lowing in vitro incubation of DEB with radiolabeled glutathione in 
cytosolic tissue fractions. Furthermore, analogous bis-glutathione 
conjugates have also been reported for hexachloro-1,3-butadiene 
(41), vinyledene chloride (42) and 1,2-dibromoethane (43). Such 
conjugates are formed via consecutive reactions of the two electro-
philic groups with two molecules of glutathione. Although the first 
reaction is catalyzed by glutathione-S-transferases, the second conju-
gation step may be either spontaneous or enzymatic (43). The result-
ing bis-glutathion-S-yl conjugates can undergo further processing by 
glutamyltransferases, cysteinyl glycinases and acetylases in the kid-
ney via the mercapturic acid pathway and are excreted in urine as the 
corresponding bis-N-acetylcysteine (mercapturic acid) conjugates. 
Fig. 4. Representative traces for nanoHPLC-NSI+-MS/MS analysis of bis-N7G-BD adduct in liver DNA of F344 rats exposed to 0 p.p.m. of BD (A) and 
62.5 p.p.m. of BD (B). Concentrations of bis-N7G-BD adducts in liver tissues of F344 rats (C) exposed to 0, 62.5 or 200 p.p.m. BD by inhalation for 2 weeks 
(6 h/day, 5 days/week). Error bars represent standard deviation values obtained upon analysis of quadruplicate samples. Statistical significance is represented for 
comparisons between exposed and control samples (P < 0.05). The differences between bis-N7G-BD adduct concentrations in liver DNA of male and female rats 
were not statistically significant (P > 0.2).
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Interestingly, Cho and Guengerich have shown that glutathione–DEB 
monoconjugates are formed in vivo and are more mutagenic than 
DEB itself (44,45).
The availability of specific urinary biomarkers for DEB, EB, 
HMVK and EBD (bis-BDMA, MHBMA, DHBMA and THBMA, 
respectively, Scheme 1), has enabled us to evaluate the formation 
of all four electrophilic metabolites of BD in vivo (BD-exposed 
rats and humans exposed to BD in the workplace or via smoking). 
Although MHBMA, DHBMA and THBMA were observed in urine 
of both species, bis-BDMA was detected in BD-treated rats, but not 
in BD-exposed humans (Figure  3). This can be explained by more 
efficient bioactivation of BD to DEB or less efficient detoxification of 
DEB in the rat as compared with humans (22).
The relative molar concentrations of MHBMA, DHBMA and 
THBMA differed significantly between the two species. In humans, 
DHBMA accounted for 93% of total urinary BD-mercapturic acids 
(Figure 3B), whereas the other three BD-mercapturic acids were much 
less abundant, with THBMA at 5%, MHBMA at 2% and bis-BDMA 
at <0.1% (Figure 3B). In contrast, in the rat, DHBMA accounted for 
only 47% of metabolites, closely followed by THBMA (37%). In 
the latter species, MHBMA comprised for 15% and bis-BDMA for 
1% of BD-mercapturic acids excreted (Figure 3A). Our results are in 
agreement with previous investigations of BD metabolism in rats and 
humans. For example, the concentrations of BD metabolites in blood 
of rats exposed to 62.5 or 200 p.p.m. BD followed the order: EB-diol 
(precursor of DHBMA) > EBD (precursor of THBMA) > EB (precur-
sor of MHBMA) > DEB (precursor of bis-BDMA) (46). Furthermore, 
the relative abundance of the corresponding hemoglobin adducts in 
blood of BD-exposed rats was THB-Val (from EBD) > HB-Val (from 
EB) > Pyr-Val (from DEB) (7).
Background amounts of MHBMA (68.5 ± 17.1 ng/ml), DHBMA 
(3192.7 ± 533.2 ng/ml) and THBMA (561.7 ± 81.7 ng/ml) were 
observed in urine of control animals exposed to filtered air only. This 
finding is consistent with a previous report by McDonald et al. (25) 
who detected MHBMA and DHBMA in urine of control F344 rats 
(10 and 1500 ng/ml, respectively). Georgieva et al. (33) also observed 
significant background levels of the corresponding BD-hemoglobin 
adducts (HB-Val and THB-Val) in unexposed rats (47), suggesting 
that there is a significant endogenous source of these metabolites in 
mammals. In our recent paper (31), we observed detectable amounts 
of THBMA in urine of non-smokers (16.3 ng/ml), although smokers 
excreted higher amounts of this metabolite (30.7 ng/ml). In contrast, 
DEB-specific biomarkers bis-N7G-BD (Figure 4) and Pyr-Val were 
not detected in control animals (33,47).
Although higher concentrations of DEB-derived bis-BDMA and 
bis-N7G-BD DNA–DNA cross-links were observed in female rats as 
compared with males (Figures 2A and 4C), these gender differences 
were not statistically significant. This is consistent with our earlier 
study, which found that bis-N7G-BD adducts were more abundant 
in female rats than in male rats following exposure to 625 p.p.m. BD 
(23). Furthermore, Boysen et  al. (48) reported that the concentra-
tions of DEB-specific hemoglobin adducts (pyr-Val) were 2- to 4-fold 
higher in female rats as compared with males following exposure to 
1000 p.p.m. BD, although no gender differences were observed fol-
lowing 200 p.p.m. BD exposure (23,33). However, we also observed 
that the relative formation of bis-BDMA was slightly higher in female 
rats as compared with male rats (Supplementary Table S3, available 
at Carcinogenesis Online), in support of possible gender differences 
in BD metabolism. Increased formation of DEB in females may be 
responsible for their enhanced susceptibility toward BD-induced can-
cer as revealed in animal inhalation studies (3).
To evaluate the correlation between urinary metabolites of DEB 
and the amounts of diepoxide bound to genomic DNA, DEB-specific 
DNA–DNA cross-links (bis-N7G-BD) were quantified in liver DNA 
of the same BD-exposed rats (Figure 4). Unlike linear dose–response 
relationships observed for bis-BDMA, bis-N7G-BD concentrations 
followed a more complex dose–response relationship, with the highest 
adduct numbers observed at a medium exposure levels (62.5 p.p.m. BD, 
see Figure 4C). It has been previously hypothesized that the metabolic 
activation of EB to DEB in the rat is saturated at high BD concentra-
tions (>62.5 p.p.m.) (23,49). Our data for urinary bis-BDMA in the 
same animals contradict this hypothesis, since urinary bis-BDMA con-
centrations continue to increase upon inhalation exposure to 62.5 and 
200 p.p.m. BD (Figure 2A). Alternatively, our observation of decreased 
levels of bis-N7G-BD adducts in the high exposure group may be 
explained by BD-mediated epigenetic changes (50), which can lead to 
the induction of DNA damage response, cell cycle arrest, senescence 
and cell death (51,52). These possibilities warrant further investigation.
In summary, the current study for the first time establishes bis-
BDMA as a novel urinary biomarker of metabolic bioactivation of 
BD to DEB. Unlike other BD-mercapturic acids, bis-BDMA is not 
present in urine of unexposed animals, suggesting that it is a specific 
biomarker of exposure to BD. Furthermore, bis-BDMA was detected 
in rats exposed to BD by inhalation, but not in occupationally exposed 
workers or smokers. Therefore, humans appear to be less efficient 
than rats in respect to metabolizing BD to DEB, revealing possible 
interspecies differences in metabolism of BD that may be highly rel-
evant to human risk assessment.
Supplementary material
Supplementary Tables S1–S3, Scheme S1 and Figures S1–S4 can be 
found at http://carcin.oxfordjournals.org/
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